Latham & Watkins Advises on Rocket Pharmaceuticals’ Growth Facility
Rocket Pharmaceuticals (RCKT) secured a $150M term loan facility led by Hercules Capital (HTGC), including a $35M initial tranche. The loans mature in 2030, with a possible extension to 2031. Rocket issued warrants for 1.76M shares at $2.99 per share. Latham & Watkins advised Hercules.
How this was made
The 30-second read
Why it matters
The $150 million facility strengthens the balance sheet but adds dilution risk, likely resulting in a modest price reaction.
Market read
Primary corporate financing news for a mid‑cap biotech; relevant for traders monitoring cash runway and dilution.
What to watch
Potential covenant restrictions and milestone‑based tranches could limit future funding if milestones are missed.
Background
Rocket Pharmaceuticals is a clinical‑stage biotech developing therapies for rare diseases. The loan is secured by its assets and IP.
Ticker impact
Rocket Pharmaceuticals announced a senior secured term loan facility up to $150 million, including a $35 million funded tranche and warrants for new shares.
modest upside as the cash infusion improves runway, tempered by potential share dilution.
Large capital raise for a clinical‑stage biotech is material; investors typically price in the cash benefit while discounting dilution.
Market effects
May signal increased financing activity for biotech firms seeking runway extensions.
Limited to U.S. biotech investors; no broader regional effect.
Low; the news is company‑specific.
Counterpoint
The warrant issuance could lead to significant dilution, outweighing the cash benefit and pressuring the stock.
Key entities
- companyRocket Pharmaceuticals, Inc.
Issuer of the loan facility.
- companyHercules Capital, Inc.
Lead lender for the term loan.
